NEWS
Eleison Pharmaceuticals LLC


Eleison Pharmaceuticals
Please scroll down and click to view pdf:

May 5, 2016 - Eleison Announces the Approval from the CFDA to Expand Enrollment to China of Eleison’s Ongoing Phase III Glufosfamide Study in Pancreatic Cancer

December 11, 2015 - Eleison Announces the Issuance of New Patents for Glufosfamide and ILC

May 1, 2015 - Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer

January 19, 2015 - Eleison Pharmaceuticals Partners with Intelgen (HK) Limited to Develop and Commercialize ILC for the China Market

October 9, 2014 - Eleison Announces Completion of Enrollment in Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer

January 3, 2014 - Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial of ILC for Pediatric Bone Cancer

October 8, 2013 - ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma

January 8, 2013 - Eleison Announces Issuance of Glufosfamide Patent

October 22, 2012 - Eleison Announces First Patient Enrolled in Phase II Trial of ILC for Pediatric Bone Cancer

February 28, 2012 - Eleison Completes Series B Private Equity Financing

October 26, 2011 - Eleison Licenses Glufosfamide to Daewoong Pharmaceuticals for Korean Market

September 9, 2011 - Eleison Announces the Appointment of Three New Members to its Science Advisory Board

April 28, 2011 - Glufosfamide Granted Orphan Drug Designation in Europe

April 7, 2011 - Eleison Pharmaceuticals Honors the Life of Dr. Baruch S. Blumberg

January 17, 2011 - Eleison Appoints Dr. Howard Hochster to its Science Advisory Board

December 1, 2010 - Eleison Pharmaceuticals Interviewed by New York Times

November 2, 2010 - Eleison Announces Notice of Award of U.S. Qualifying Therapeutic Discovery Grants

July 7, 2010 - Eleison Appoints Dr. Baruch Blumberg to its Science Advisory Board

May 26, 2010 - Eleison Announces Agreement with FDA on a Special Protocol Assessment (SPA) for a Phase III Clinical Trial of Glufosfamide in Pancreatic Cancer

October 15, 2009 - Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals